Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In the 36 months since its inception, the National Prostatic Cancer Project treatment subgroup has randomly assigned over 360 patients with progressive advanced prostatic cancer who were no longer responsive to endocrine manipulation to either one of four different clinical studies. The initial study demonstrated a clear superiority for 5-fluorouracil (5-FU) and cyclophosphamide over continued conventional therapy. Beneficial responses were documented and are associated with increased survival rates and relief from pain and other symptoms. A proportionately larger number of patients obtained clinical benefit (stable and partial regression) on cyclophosphamide than on standard or 5-FU therapy. The criteria for evaluation of patients are supported by the survival data, ie, responders have survived for a longer period of time than those patients who continued in progression. Preliminary data from the subsequent protocols have documented a 30% response (stable and partial regression) in patients receiving oral estramustine phosphate and definite responses in patients treated with DTIC; Too few patients have been treated with Leo 1031 to offer total response rates at this time, although the early results are promising. These clinical studies have firmly established a place for chemotherapy in the management of prostatic cancer. New trials will introduce single- and multiple-drug chemotherapy at earlier phases of the clinical course of prostatic cancer patients.
 ...
PMID:National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: a progress report. 14 26

The diagnostic sensitivity (Se) and specificity (Sp) of fine-needle aspiration cytology (FNAC) of the prostate can be evaluated by comparing its results to a histological reference: rates of reported Se range from 65-98%, Sp being equal or superior to 95%. Published series are heterogeneous in terms of cancer prevalence, with a 25-85% proportion of histologically proven adenocarcinomas, irrespective of the anatomical stage of the disease. The overall accuracy of screening by core biopsies or FNAC is lower than 5%, and does not justify wide-scale application of these tests. In 75%, cytological assessment of the tumor grade correlates with Gleason's histological score and grade. Severe intraductal dysplasias (DIC 3) are probably involved in some of the cytological grade I cases. Ultrasonographic guidance of FNAC is not recommended in comparison with histologically obtained data. The indications for performing FNAC of the prostate should be different from those of standard biopsies: the former should be carried out on suspicious lesions revealed by digital rectal examination or ultrasonography, or in a staging attempt. FNAC should be reserved for early diagnosis of prostate cancer in patients presenting with non-specific urologic symptoms. Samples should be obtained by digitally-guided transrectal bilateral FNAC.
 ...
PMID:[Cytology in the positive diagnosis and grading of prostatic cancers: which indications do remain at the time of automatic biopsies and endorectal echography?]. 152 Sep 54

The authors present their experience about the accuracy of staging and the results of radical prostatectomy in prostatic cancer. From january 1978 to september 1988, 47 patients with clinically localized prostatic carcinoma underwent staging pelvic lymphadenectomy, of whom 36 had proven negative pelvic lymph nodes and 1 had only a micrometastasis in the obturatory nodes. We reviewed the surgical results and survival of these 37 patients who underwent radical prostatectomy. The postoperative complications were compared to those reported in Literature: partial incontinence occurred in 3 patients and there were no symptomatic urethral strictrues. 1 patient died in the early postoperative period by DIC. 35 patients are alive, 27 free of disease, with average follow-up of 36 months. The over-all accuracy of staging was 87%. Our experience suggests that radical prostatectomy with staging bilateral pelvic lymphadenectomy can be performed in a safe manner with minimal postoperative morbidity.
 ...
PMID:[Cancer of the prostate. Clinical estimation and results of radical prostatectomy]. 268 97

In summary, the completed NPCP clinical trials have demonstrated that treatment with single antitumor agents and some combinations provide potential benefit to men with metastatic disease, both in those who have failed conventional hormonal therapy as well as those with newly diagnosed metastatic lesions. A summary of overall objective response rates in trials conducted on hormone-refractory patients is shown in Tables 17 and 18. In addition to demonstrating that chemotherapy can elicit a favorable response in patients with relapsing stage D disease, the NPCP has demonstrated that patients who respond to chemotherapy survive significantly longer than nonresponders. Furthermore, it has been demonstrated in these patients that objective partial regressions have been seen only with chemotherapy. Active single agents in prostatic cancer include methotrexate, cis-platinum, Estracyt, cyclophosphamide, 5-FU, DTIC, and streptozotocin. Finally, there may be some benefit in terms of response rate and survival when adding chemotherapy to conventional hormone therapy in patients with previously untreated stage D disease.
 ...
PMID:Results of trials of the USA National Prostatic Cancer Project. 389 31

Results of the first randomized trial of the National Prostatic Cancer Project (NPCP) revealed an advantage for cytoxan and 5-FU over standard therapy in hormonally resistant stage D prostate carcinoma. A subsequent trial for patients previously irradiated, receiving the less myelosuppressive agents estracyt or streptozotocin also revealed an advantage over standard therapy. Other completed randomized trials have revealed activity for prednimustine and DTIC. Trials underway for newly diagnosed stage D disease or for stage D disease clinically stable to diethylstilbestrol (DES) show promising activity for cytoxan and DES combined. Current randomized trials in advanced disease are comparing methyl CCNU and hydroxyurea wih cytoxan, and estracyt or vincristine alone or in combination. Chemotherapy in earlier staged patients as adjuvants to definitive surgery or irradiation is underway in two trials, comparing the effects of cytoxan or estracyt as long-term therapies with no additional treatment.
 ...
PMID:The chemotherapy of prostatic carcinoma. 693 19

Carcinoma of the prostate has historically been associated with the bleeding diathesis which accompanies disseminated intravascular coagulation. We have performed a prospective study into the prevalence of coagulopathy in patients with untreated prostate cancer using matched patients with benign prostatic hypertrophy (BPH) as controls. Haemostatic activation was assessed by measuring fibrinopeptide A (FpA) by an ELISA and D-dimer by a latex agglutination assay. FpA and D-dimer levels were correlated with serum prostate specific antigen (PSA) and bone scan status. Of the cancer patients, 40% had elevated FpA, levels being higher in those with bone scan positive disease (P < 0.05). D-dimer was detectable in 24% of those with prostate cancer but in none with BPH. Neither FpA nor D-dimer were related to serum PSA but D-dimer appeared to be a predictor of bone scan status with a positive predictive value of 91%. It is concluded that changes compatible with subclinical DIC are common in patients presenting with prostate cancer and that measurement of FpA and D-dimer may have roles as tumour markers in this disease.
 ...
PMID:Coagulopathy in the prostate cancer patient: prevalence and clinical relevance. 768 95

Pre-operative and operative complications in 2266 patients having undergone transurethral resection of prostate (TURP) for the past 20 years at Kitasato University Hospital were analyzed. They consisted of 2008 benign prostatic hyperplasia and 258 prostate cancer patients. Seven hundred and fifty four patients showed some of physical disorders prior to TUR:hypertension in 147 cases, diabetes mallitus in 87, ischemic heart disease in 46, chronic obstructive lung disease in 41 and others. Operative and postoperative complications of TURP were seen in 308 cases (13.6%). Perforation of the prostatic capsule was seen in 100 cases (4.4%) and bladder perforation into intraperitoneal cavity in 6 cases (0.3%). Transurethral fulgulation for postoperative hemorrhage was conducted on 79 cases (3.5%). Hyponatremia lower than 130 mEq/L was noted in 14 cases (0.6%). Severe urinary tract infection leading to bacteremia was observed in 9 cases (0.4%). Postoperative epididymitis was evident in 20 cases (0.8%). There was postoperative urinary incontinence in 19 cases, 3 of which was treated with Teflon-paste injection successfully. One patient had to undergo AMS-800 artificial sphincter implantation. The number of postoperative urethral stricture patients requiring urethral dilatation or internal urethrotomy was 12 (0.5%) and postoperative bladder neck contracture was seen in 20 cases (0.9%). One patient (0.04%) who developed DIC after profuse postoperative hemorrhage died on the 37th postoperative day. The efficiency of TURP depends not so much on the skill of cutting as on the speed and accuracy of orientation and haemostasis. The quick recognition of anatomical landmarks will assure effective and safe resection.
 ...
PMID:[Pre-operative, operative and postoperative complications in 2266 cases of transurethral resection of the prostate]. 768 90

Eleven patients with chronic subdural hematoma (CSDH) with bleeding tendency (BT) were surgically treated in the last 12 years. To study the clinical problem of CSDH with BT, 11 surgical cases were divided into 3 groups, Group A; CSDH with primary BT (1 case of hemophilia A), Group B; CSDH with BT secondary to a basic disease (3 cases of leukemia, 2 cases of malignant tumor with DIC, 1 case of chronic renal failure and 1 case of liver cirrhosis), Group C; CSDH with BT by anticoagulants (warfarin) (2 cases of replacement of mitral valve, 1 case of A-C bypass). Evacuation of the hematoma was performed by means of one or two burr holes with irrigation of the hematoma cavity and a drainage tube was placed in the subdural space. The outcome was excellent in Groups A and C. In Group B, two patients with DIC due to gastric cancer and prostatic cancer died, and 3 patients with leukemia recovered dramatically from CSDH, but the poor course of the disease itself resulted in death. The outcome of other patients in Group B was excellent. Since CSDH with BT is often fatal, those patient had usually been treated conservatively. However, from this analysis, we stress that CSDH with BT should be surgically treated after checking the blood conditions carefully to determine whether or not the patient has need for surgery.
 ...
PMID:[Chronic subdural hematoma with bleeding tendency; clinical analysis of 11 surgical cases]. 784 20

In men with hormone refractory metastatic prostate cancer, single agents have demonstrated an objective response when using a response rate greater than standard treatment in prior National Prostate Cancer Project (NPCP) trials. Among these agents are methotrexate, cisplatin, 5-fluorouracil, cyclophosphamide, doxorubicin, estramustine, methyl N-(2-chloroethyl)-N'-cyclohexyl-Nnitrosourea (CCNU), 5-(3,3-dimethyl1-triazenyl)1H-imidazole-4-carboxamide (DTIC), and vinblastine. Other combinations of protocols have been previously evaluated. Currently under review is a 1 4-year follow-up on an adjuvant trial (NPCP 900/1000) where all patients had a bilateral pelvic lymphadenectomy. These patients were then randomized to surgery or radiation, and received either cyclophosphamide, estramustine, or no therapy for 2 years. Clinical results showed there was no difference in disease-free survival or survival rates between those patients in the group who had T3 prostate cancer, and those with negative pelvic lymph node dissection. The drugs diethylstilbestrol, megestrol, or streptozocin have been used. In clinical trials, the single agent diethylstilbestrol usually had a better effect. Combinations of estramustine with vinblastine were also effective when compared with the results of standard treatment. When comparing patients who relapsed from hormone refractory prostate cancer, there was no significant statistical response rate difference (P = <0.05) in patients who were offered either flutamide or estramustine. To determine more accurately the positive results from these trials, the pre-prostate-specific antigen (PSA) era of stable disease must be re-evaluated.
 ...
PMID:Review of phase II hormone refractory prostate cancer trials. 1060 80

A 55-year-old man with prostate cancer received a total prostatectomy. Two days after the operation, he suffered from high fever and shaking chilliness, followed by skin eruption, hypotension, diarrhea and chest pain. The results of blood bacterial culture and endotoxin were negative. Toxic shock syndrome was suspected, and the administration of vancomycin (VCM) and continuous hemodialysis-filtration (CHDF) were performed. The steroid pulse therapy for adult respiratory distress syndrome (ARDS) and the treatments for DIC were also done, and they were effective. The desquamation of the extremity was observed on 10 days after the operation. MRSA was finally identified from pus discharge of the operation wound 13 days after the operation. The prevention and treatments for toxic shock syndrome were discussed.
 ...
PMID:[Toxic shock syndrome due to methicillin resistant staphylococcus aureus (MRSA) after total prostatectomy]. 1184 39


1 2 Next >>